ChordNews
← All news

Halozyme projects 2026 revenue of $1.86B-$1.925B and raises non-GAAP EPS outlook to $8.75-$9.05

By ChordNews · First written (updated )

Comments 0

Summary

Halozyme expects 2026 revenue of $1.86B to $1.925B and has raised its non-GAAP earnings-per-share outlook to $8.75 to $9.05, according to a Seeking Alpha headline published November 6, 2026. The headline is the only reporting available, so no drivers, further figures or context are confirmed.

This continues an earlier story: Amgen projects 2026 revenue of $38.9B-$39.7B while raising non-GAAP EPS to $22.90-$23.70

Timeline

  1. Seeking Alpha

    Source ↗

    Seeking Alpha reports that Halozyme expects 2026 revenue of $1.86B-$1.925B while raising its non-GAAP EPS outlook to $8.75-$9.05.

Comments

No comments yet.

    to like and comment.

    © 2026 ChordNews